This case study outlines a randomised, double-blind, placebo-controlled, Phase II study evaluating the efficacy and safety of Study Drug A in combination with Study Drug B administered as first-line treatment to subjects with unresectable, locally advanced, or metastatic pancreatic adenocarcinoma.

PRA was awarded a global, full-service Phase II pancreatic cancer trial by a biotech client. The project was originally launched by a different company that PRA’s client had acquired. The first sites were opened in October, with first patient-in occurring in January.

PRA’s key challenges included study start-up delays and client communication issues